News-Medical.Net

Blocking growth hormone receptor may improve treatment response in lung cancer

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Growth hormone receptor could serve as possible target for improving lung cancer treatment

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
The Malaysian Reserve

FDA approves Novo Nordisk’s Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Gestational ...
Ohio University

New study identifies growth hormone receptor as possible target to improve lung cancer treatment

Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.